Mezgebe Berhe

机构：Baylor University Medical Center, Infectious Disease Consultants · ORCID：0000-0002-7287-567X

发表论文 52 篇 · 总被引 1669 次 · h-index 16

代表论文

• Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection (2022 · New England Journal of Medicine · 被引 312)
• Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial (2022 · The Lancet Respiratory Medicine · 被引 130)
• Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial (2022 · The Lancet Respiratory Medicine · 被引 128)
• Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial (2022 · The Lancet HIV · 被引 107)
• Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial (2023 · The Lancet HIV · 被引 71)
• The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19 (2022 · Annals of Internal Medicine · 被引 63)